Spinal cord stimulation is a minimally invasive surgical treatment for severe, chronic, neuropathic pain that is refractory to conventional treatment. The treatment consists of an electrode implanted in the epidural space of the spinal cord, either via a percutaneous approach (using the so-called percutaneous leads) or via a surgical (hemi-) laminectomy (using the so-called surgical leads or plate leads). It is a well-known clinical observation that when activating or deactivating SCS stimulation, there is a variable interval before the patient perceives a clinical effect of the change. This variation goes by different names (carryover, echo, after effect, etc.) and might be dependent on the clinical condition and treatment duration. To our knowledge only very little research has been published on the topic of carryover effects; a recent study showed that the interval is highly variable between patients. While patients may experience immediate pain relief at the onset of SCS treatment, the effect in patients with a long-term SCS treatment history may have different characteristics, possibly due to ongoing changes in the nervous system. The aim of this pilot study is to lay the foundation for investigating the carryover effects in spinal cord stimulation. This will be carried out in a mixed population of patients with different indications for SCS, and with different treatment durations. Patients will be asked to deactivate their device via their remote control or with a magnet in a standardized fashion. They will be asked to reactivate the device when specific parameters have been met, and the time is recorded.
In the post-hoc analysis the carryover and reverse carryover effect will be analyzed and correlated to a number of parameters including, but not limited to: Indication, treatment duration, symptom duration, preoperative pain score, stimulation paradigm, gender, age. Data will be collected and stored using a dedicated REDCap database under the auspices of Aarhus University.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
200
Patient-controlled, temporary deactivation of implanted device
AZ Delta Roeselare/Menen/Torhout
Roeselare, Belgium
CHU de Québec - Université Laval
Québec, Quebec, Canada
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Odense University Hospital
Odense, Denmark
Diakovera Friederikenstift
Hanover, Germany
Medisch Spectrum Twente
Enschede, Overijssel, Netherlands
Erasmus University Medical Center
Rotterdam, Netherlands
Sahlgrenska University Hospital
Gothenburg, Sweden
Sunderby Hospital
Luleå, Sweden
Carryover/echo effect: Time from deactivation of device to cessation of treatment affect
Time from deactivation of device to cessation of treatment affect
Time frame: Up to one week (may be repeated)
Reverse carryover/echo effect: Time from reactivation of device to full reestablishment of treatment effect
Time from reactivation of device to full reestablishment of treatment effect
Time frame: Up to one week (may be repeated)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.